Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.

Stryker's (SYK) Q3 Earnings Miss Estimates, Volume Improves

Stryker Corporation (NYSE:SYK ) Q3 2022 Earnings Conference Call October 31, 2022 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Glenn Boehnlein - Chief Financial Officer Jason Beach - Vice President, Investor Relations Conference Call Participants Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Matthew O'Brien - Piper Sandler Joshua Jennings - Cowen & Co. Matthew Miksic - Barclays Rick Wise - Stifel Drew Ranieri - Morgan Stanley David Saxon - Needham & Company Steven Lichtman - Oppenheimer Ryan Zimmerman - BTIG Matthew Taylor - Jefferies Samuel Brodovsky - Truist Securities Jayson Bedford - Raymond James Jeff Johnson - Baird Operator Welcome to the Third Quarter 2022 Stryker Earnings Call. My name is Megan, and I'll be your operator for today's call.

Stryker Corporation (SYK) Q3 2022 Earnings Call Transcript

Stryker (SYK) delivered earnings and revenue surprises of -5.36% and 0.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Misses Q3 Earnings Estimates

Shares of Stryker Corp. SYK, +0.00% fell more than 4% in the extended session Monday after the maker of surgical equipment and other medical devices reported third-quarter results above analyst expectations but lowered its profit outlook for the year, thanks to inflation and a stronger dollar. Striker earned $816 million, or $2.14 a share, in the quarter, compared with $495 million, or $1.14 a share, in the year-earlier period.

Stryker Corp. stock falls after company lowers outlook for 2022

Kalamazoo, Michigan, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2022:

Stryker reports third quarter 2022 operating results

Intuitive Surgical

Johnson & Johnson

As surgeries bounce back toward pre-pandemic levels, these three companies should benefit.

3 Medical Stocks On the Rebound

Stryker to Showcase Innovative Portfolio of Spine Solutions at the North American Spine Society Meeting

Archer-Daniels-Midland Company

BioNTech SE

EOG Resources

Medtronic

Pfizer

Are you looking for a relatively safe mutual fund haven amid current market carnage? Check out Madison Covered Call & Equity Income Fund (MENYX).

Income Plus Low Volatility Makes This Fund A Safe Haven

I've been taking long looks at dividend-paying solid companies with relatively low yield, but very high safeties. Stryker is my latest in a long line of this. Stryker is a multinational MedTech business based out of Michigan. They have specific niches in implants, surgical equipment and endoscopy as well as communication systems.

Stryker - A Leading MedTech Company Worth A Second Look

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker launched its Monterey AL Interbody System, a stand-alone interbody fusion device designed for anterior lumbar interbody fusion.

Stryker Launches Monterey AL Interbody System with New Pre-clinical Data

Kalamazoo, Michigan, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Monday, October 31, 2022 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ending September 30, 2022 and provide an operational update. Final operating results for the quarter will be released at 4:05 p.m. that day.

Stryker to host conference call on October 31, 2022

Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.

Stryker (SYK) Launches Q Guidance System for Spine Applications

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker announced the launch of its Q Guidance System for spine applications.

Stryker Launches Q Guidance System with Spine Guidance Software

Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.

Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod

Dover

Polaris

Income investors sometimes take the route of finding the best income stocks to meet their needs based upon criteria like dividend safety, dividend growth potential or historical dividend streak. These can help investors find great dividend champions that will provide them with years of income.

3 Undervalued Dividend Champions With High Return Potential

Stryker Corporation (NYSE: SYK) is a “mispriced” stock that has potential to offer lucrative returns over the long term, says Heather Brilliant. She's the Chief Executive of Diamon Hill Capital Management.

Diamon Hill CEO names a ‘mispriced' medical technology stock

Stryker's first bone tumor ablation system with patented microinfusion technology offers a reliable solution for people living with painful metastatic tumors PORTAGE, Mich., USA, Sept.

Stryker receives FDA clearance for OptaBlate™ Bone Tumor Ablation System

Stryker stock (NYSE: SYK), a medical devices company, has seen a 15% fall this year, in line with the broader S&P500 index, down 17%.

Should You Buy Stryker Stock Around $225?

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker launched its Pulse Intelligent Delivery Platform, which will debut at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting.

Stryker Launches Pulse Intelligent Delivery Platform at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker has launched the Gamma4 System, strengthening the product's 30-year legacy of continuous innovation and clinical history.

Stryker Launches New Gamma4 Hip Fracture Nailing System

Stryker Corporation ( SYK , Financial) has long been one of my favorite health care names as the company provides some market-leading medical devices.

Why Stryker Remains a Top Health Care Name

Kalamazoo, Michigan, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2022 Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2022.

Stryker to participate in the 2022 Wells Fargo Securities Healthcare Conference

Stryker's medical devices reach more than 100 million patients each year.

Why This Dividend Stock Is a Buy

Stryker is a diversified medical technology company with strong sales growth, profitability, and a long history of dividend growth. It's well positioned to invest in strategic growth areas and benefits from favorable demographic tailwinds.

Stryker Is A Moat-Worthy Buy, Here's Why

Kalamazoo Michigan, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.695 per share payable October 31, 2022 to shareholders of record at the close of business on September 30, 2022, representing an increase of 10.3% versus the prior year and unchanged from the previous quarter.

News for Stryker Stock (SYK)